Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Alpha Cognition Inc C.ACOG

Alternate Symbol(s):  ACOGF

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

CSE:ACOG - Post Discussion

Alpha Cognition Inc > $ACOG Update
View:
Post by SkywalkerofLuke on Dec 29, 2021 2:38pm

$ACOG Update

$ACOG.v $ACOGF on Monday gave an update on the company.


Their team


- Dr. Fred Sancilio (Director and President) is resigning and taking a smaller role

- Dr. Cedric O’Gorman, the Chief Medical Officer, will take over some of the roles Dr. Sancilio held


As well they announced upcoming plans


- Accelerating the ALPHA-0602 progranulin pre-clinical study (on track to release data in the first Q of 2022)

- Excited to complete a pivotal relative bioavailability study of ALPHA-1062 (designed to treat mild to moderate Alzheimer’s Disease)

- Set of trials, if successful, will allow $ACOG to submit an NDA for ALPHA-1062 in the second half of 2022


Some exciting stuff to look forward to in 2022, IMO not one to miss. 


https://www.businesswire.com/news/home/20211227005106/en/

Be the first to comment on this post
Alpha Cognition Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities